Leo Pharma's new drug for atopic dermatitis receives EU approval

Leo Pharma received a recommendation from the expert panel of the European Medicines Agency in April, and the commission has followed this advice, approving the eczema treatment Adtralza from the Danish company.

Photo: Leo Pharma / PR

Now, Leo Pharma can get properly started on launching the drug Adtralza in the EU.

Tuesday, the EU Commission ratified the former recommendation for approval, which the Committee for Medicinal Products for Human Use (CHMP) gave Adtralza in April, according to a press release from the company.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs